Trial Profile
A phase I study assessing single and multiple doses of IDX21459 in healthy and HCV-infected subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs IDX 21459 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 28 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Apr 2014 New trial record